Does Medicare Advantage Cover Actos (Pioglitazone)?

Medicare Part D Formulary Placement for Pioglitazone

Generic pioglitazone sits on the preferred generic tier of the large majority of Medicare Advantage Part D formularies. This means low out-of-pocket costs and minimal administrative barriers for beneficiaries with a type 2 diabetes diagnosis.

Since pioglitazone lost patent exclusivity in 2012, generic versions from manufacturers such as Teva, Mylan, and Sun Pharma have driven the average cash price down to roughly $15 per month at retail pharmacies. Medicare Advantage plans pass those savings along. According to CMS formulary files published for the 2025 plan year, pioglitazone 15 mg, 30 mg, and 45 mg tablets appear on the formularies of plans covering over 95% of Medicare Advantage enrollees nationwide. The FDA-approved prescribing information lists the available strengths as 15 mg, 30 mg, and 45 mg, with a maximum recommended dose of 45 mg once daily.

Tier placement matters. A Tier 1 (preferred generic) placement means $0 to $5 copays in most plans. Tier 2 (generic) placement raises copays to $5 to $15. Brand-name Actos, if requested by the prescriber through a formulary exception, would land on Tier 3 or higher, potentially costing $30 to $60. There is almost never a clinical reason to prescribe brand Actos over generic pioglitazone, and most plans enforce generic substitution automatically.

Beneficiaries enrolled in plans with the Part D Low-Income Subsidy (LIS, or "Extra Help") pay $0 for preferred generics and no more than $4.50 for non-preferred generics under 2025 CMS cost-sharing limits. The CMS LIS fact sheet outlines current thresholds. For dual-eligible enrollees, pioglitazone carries zero copay in most states.

Prior Authorization: When It Applies and When It Does Not

For the FDA-approved indication of type 2 diabetes, most Medicare Advantage plans do not require prior authorization for pioglitazone. The drug is prescribed, the pharmacy processes the claim, and the plan pays. Simple.

Complexity enters when prescribers use pioglitazone off-label. The two most common off-label scenarios are nonalcoholic steatohepatitis (NASH, now called metabolic dysfunction-associated steatohepatitis or MASH) and insulin resistance syndromes not meeting the diagnostic threshold for type 2 diabetes. For these uses, many plans flag the claim and request clinical documentation before approving coverage.

A typical prior authorization request for off-label pioglitazone requires: (1) a confirmed diagnosis with supporting labs or imaging, (2) documentation that the prescriber has considered FDA-approved alternatives, and (3) clinical rationale citing published evidence. The PIVENS trial (Sanyal et al., NEJM 2010, N=247) showed that pioglitazone 30 mg daily for 96 weeks produced histological improvement in NASH in 34% of patients versus 19% on placebo (P=0.04), making it one of the strongest evidence-backed off-label uses of any thiazolidinedione [1]. Including this citation in the prior auth submission strengthens the clinical case.

The American Association for the Study of Liver Diseases (AASLD) 2018 practice guidance states that pioglitazone can be used to treat biopsy-proven NASH in patients with or without type 2 diabetes, noting: "Pioglitazone improves liver histology in patients with NASH" [2]. Quoting this guideline directly in a prior auth letter carries weight with plan medical directors.

Step Therapy Requirements Across Major Plans

Some Medicare Advantage plans impose step therapy for thiazolidinediones, requiring a trial of metformin (and sometimes a sulfonylurea or SGLT2 inhibitor) before approving pioglitazone. This reflects the American Diabetes Association Standards of Care, which recommend metformin as first-line pharmacotherapy for most adults with type 2 diabetes [3].

Step therapy does not mean pioglitazone is unavailable. It means the plan wants documentation that first-line therapy was tried, was insufficient, or was contraindicated. For patients with metformin intolerance (gastrointestinal side effects affect up to 25% of users according to a Cochrane review) or chronic kidney disease with eGFR <30 mL/min (where metformin is contraindicated per FDA labeling), the step therapy requirement is waived immediately [4].

Plans from UnitedHealthcare Medicare Advantage (AARP), Humana, Aetna, and CVS/SilverScript generally do not enforce step therapy for pioglitazone when the ICD-10 code submitted is E11.x (type 2 diabetes mellitus). Plans from smaller regional carriers and some Cigna Medicare Advantage products have been more likely to layer step therapy onto TZD claims. The specific requirement varies by plan year and region.

If your plan requires step therapy and your prescriber believes pioglitazone is clinically appropriate as a first or second-line agent (for example, in a patient who also has biopsy-proven NASH and would benefit from pioglitazone's dual hepatic and glycemic effects), the prescriber can request a step therapy exception. The CMS Medicare Managed Care Manual, Chapter 18 requires all Part D sponsors to maintain an exceptions process and respond within 72 hours (24 hours for expedited requests) [5].

Pioglitazone for Weight Loss: Why Medicare Will Not Cover It

Federal CMS rules prohibit Part D plans from covering drugs prescribed solely for weight loss or cosmetic purposes. This exclusion was codified in Section 1860D-2(e)(2)(A) of the Social Security Act and has been in effect since the inception of Part D in 2006. While Congress passed the Treat and Reduce Obesity Act provisions allowing coverage of FDA-approved anti-obesity medications for beneficiaries with a BMI of 30 or greater (or 27 with comorbidities) beginning in 2025 through CMS rulemaking, pioglitazone does not carry an FDA-approved weight-loss indication.

Pioglitazone actually tends to cause weight gain, not loss. In the PROactive trial (N=5,238), patients randomized to pioglitazone gained a mean of 3.6 kg over 34.5 months compared to placebo [6]. The PROactive study (Dormandy et al., Lancet 2005) was designed to evaluate cardiovascular outcomes, not weight, but the weight gain signal was consistent across subgroups [6]. Any claim that pioglitazone aids weight loss would contradict the clinical trial database and the FDA label.

If a Medicare Advantage plan denies pioglitazone with a reason code indicating "weight loss exclusion," this likely reflects an incorrect diagnosis code on the claim. The prescriber should resubmit with the correct ICD-10 code (E11.x for type 2 diabetes, K75.81 for NASH/MASH) and include a brief clinical note confirming the therapeutic intent.

How to Appeal a Medicare Advantage Denial of Pioglitazone

Denials happen. When they do, the Medicare Advantage appeals process follows a structured five-level pathway established by federal regulation [42 CFR §422.560-622]. For a Part D drug denial, the relevant steps are:

Level 1: Plan Redetermination. The enrollee or prescriber submits a written request to the plan within 60 days of the denial notice. The plan must respond within 7 days (72 hours for expedited). Include the prescriber's letter of medical necessity, relevant lab results, and citations to clinical guidelines.

Level 2: Independent Review Entity (IRE). If the plan upholds the denial, the case automatically forwards to MAXIMUS Federal Services, the CMS-contracted IRE. MAXIMUS reviews the clinical evidence independently. The IRE must decide within 7 days (72 hours expedited). According to CMS data on Part C and D appeals, IREs overturn plan denials in approximately 40 to 50% of prescription drug cases that reach this level [7].

Level 3: Office of Medicare Hearings and Appeals (OMHA). Requires that the amount in controversy meets the annual threshold ($195 in 2025). For a $15/month generic, 13 months of denied coverage would meet this threshold.

The practical advice: most pioglitazone denials for diabetes resolve at Level 1. For NASH, expect to reach Level 2 before obtaining coverage. For any non-FDA-approved indication, attach peer-reviewed evidence. The PIVENS trial [1], the AASLD guidance [2], and the ADA Standards of Care [3] form a strong evidentiary package.

Off-Label NASH/MASH Coverage: Building the Clinical Case

Pioglitazone remains one of only two pharmacotherapies (alongside vitamin E) recommended by the AASLD for biopsy-proven NASH without cirrhosis. No FDA-approved therapy for NASH existed until resmetirom (Rezdiffra) received accelerated approval in March 2024 for MASH with moderate-to-advanced fibrosis. For patients who do not meet the fibrosis stage criteria for resmetirom, pioglitazone is the evidence-based pharmacologic option.

The evidence base extends beyond PIVENS. A meta-analysis by Musso et al. (2017, BMJ) pooling 8 randomized controlled trials (N=516) found that pioglitazone reduced hepatic steatosis, inflammation, and fibrosis in NASH patients regardless of diabetes status, with a number needed to treat of 5.4 for histological improvement [8]. The Musso et al. meta-analysis is among the most cited analyses in NASH therapeutics [8].

When seeking Medicare Advantage coverage for pioglitazone prescribed for NASH, the prescriber's letter should include: biopsy or imaging confirmation of steatohepatitis, the patient's fibrosis stage, whether the patient has concurrent type 2 diabetes (which simplifies approval since the drug is on-label for diabetes), and specific citations to AASLD guidelines. If the patient carries both an E11.x and a K75.81 diagnosis code, submitting the E11.x as primary often avoids the prior auth trigger entirely while remaining clinically accurate.

Cost Comparison: Generic Pioglitazone vs. Brand Actos on Medicare

The economic argument for generic pioglitazone is straightforward. Brand-name Actos carries a wholesale acquisition cost (WAC) near $60 per month. Generic pioglitazone costs $3 to $15 per month at retail, and Medicare Part D plans negotiate further discounts through pharmacy benefit managers.

For a Medicare Advantage enrollee on a standard plan (not LIS-eligible), the out-of-pocket cost trajectory through 2025 is shaped by the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D, effective January 1, 2025. Pioglitazone is so inexpensive that it would consume only a small fraction of that cap. For beneficiaries taking multiple brand-name medications, the low cost of generic pioglitazone effectively subsidizes headroom for costlier prescriptions.

Manufacturer savings cards (also called copay cards or coupons) from Takeda for brand Actos exist, but federal anti-kickback statute regulations prohibit their use by Medicare beneficiaries. This is a federal law applicable to all federally funded health programs, not a plan-specific rule. Beneficiaries who attempt to use a manufacturer coupon at the pharmacy will have the coupon rejected at the point of sale when Medicare is the primary payer. The only exception is manufacturer-sponsored Patient Assistance Programs (PAPs) that provide the drug at no cost outside the Part D benefit, which are rare for pioglitazone given the low generic price.

Safety Considerations That Affect Coverage Decisions

Plan formulary committees weigh safety data when setting coverage policies. Pioglitazone carries black box warnings for congestive heart failure exacerbation (NYHA Class III/IV) and a population-level signal for bladder cancer risk. The 10-year Kaiser Permanente cohort study (Lewis et al., JAMA Internal Medicine 2015, N=193,099) found no statistically significant increase in bladder cancer incidence with pioglitazone use (HR 1.06 to 95% CI 0.89-1.26), though the FDA maintained the label warning [9].

These safety signals do not typically affect coverage, but they do affect utilization management. Some plans require an annual attestation that the prescriber has assessed cardiac function and bladder cancer risk factors before renewing pioglitazone authorization. The Endocrine Society clinical practice guideline on pharmacological management of type 2 diabetes (2022) recommends TZDs as a third-line option after metformin and an SGLT2 inhibitor or GLP-1 receptor agonist in patients without heart failure [10].

For patients with concurrent heart failure (NYHA Class I-II), pioglitazone may still be prescribed with monitoring, but some plan medical directors require echocardiography documentation within 12 months. Plans cannot deny coverage solely based on a theoretical risk if the prescriber has documented appropriate clinical assessment.

Switching Plans During Open Enrollment to Improve Coverage

Medicare Advantage Annual Enrollment Period (AEP) runs October 15 through December 7 each year. Beneficiaries dissatisfied with their plan's pioglitazone coverage, whether due to step therapy requirements, high copays for brand Actos, or prior auth barriers for NASH, can use the Medicare Plan Finder tool at medicare.gov to compare formularies.

Enter pioglitazone into the Plan Finder drug list, select your preferred pharmacy, and the tool displays each available plan's tier, copay, and restrictions for your ZIP code. Plans with Tier 1 placement and no prior auth for pioglitazone are identifiable in minutes. The CMS Medicare Plan Finder updates formulary data quarterly, and the AEP version reflects the upcoming plan year [11].

Beneficiaries who receive a mid-year formulary change notice (plans can remove drugs from formulary with 60 days' notice after the plan year begins) may qualify for a Special Enrollment Period to switch plans outside AEP. CMS requires plans to provide a temporary transition supply of at least 30 days for enrollees affected by formulary changes.